BioVie Inc. (NASDAQ:BIVI) Short Interest Update

BioVie Inc. (NASDAQ:BIVI) was the recipient of a significant increase in short interest during the month of February. As of February 15th, there was short interest totalling 1,790,000 shares, an increase of 21.8% from the January 31st total of 1,470,000 shares. Based on an average daily trading volume, of 1,080,000 shares, the short-interest ratio is currently 1.7 days.

BioVie Trading Up 2.5 %

BioVie stock opened at $1.22 on Thursday. The firm has a market capitalization of $22.51 million, a price-to-earnings ratio of -0.12 and a beta of 0.51. The firm’s fifty day moving average price is $1.87 and its two-hundred day moving average price is $2.28. BioVie has a 1-year low of $1.04 and a 1-year high of $9.25.

BioVie (NASDAQ:BIVI) last announced its quarterly earnings results on Tuesday, February 11th. The company reported ($0.46) earnings per share for the quarter.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Millennium Management LLC bought a new position in BioVie during the 4th quarter valued at $245,000. Geode Capital Management LLC increased its stake in BioVie by 223.3% in the 4th quarter. Geode Capital Management LLC now owns 123,408 shares of the company’s stock valued at $247,000 after buying an additional 85,234 shares during the last quarter. Drive Wealth Management LLC bought a new position in shares of BioVie during the 4th quarter worth approximately $120,000. Bank of Montreal Can purchased a new position in shares of BioVie in the 4th quarter worth approximately $100,000. Finally, Sanders Morris Harris LLC bought a new position in shares of BioVie in the fourth quarter valued at approximately $85,000. Institutional investors own 4.59% of the company’s stock.

BioVie Company Profile

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.